Clinical Trial Update: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Obstructive Cardiomyopathy

Drugs mentioned

• CAMZYOS (MAVACAMTEN)
• Mavacamten (mavacamten)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HOCM, Hypertrophic Obstructive Cardiomyopathy | Phase 3 | Status: COMPLETED | Results posted: 2023-03-07